This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Important Update: Emergency Use Authorization labeled PAXLOVID will no longer be authorized for emergency use after March 8, 2024. Please click here to learn more.
PAXCESSTM Patient Support Program is now available for patients prescribed PAXLOVID. Commercially insured patients may pay as little as $0* for their prescription by downloading a co-pay card here.
Patients on Medicare, Medicaid, TRICARE, VA Community Care Network, and those who are uninsured may enroll in the U.S. Government’s Patient Assistance Program (USG PAP)† operated by Pfizer to access PAXLOVID for free through December 31, 2024, here.
For more information, visit the website access page here or call 877-C19-PACK (877-219-7225).
*Eligible commercially insured patients can save up $1,500 per prescription. Maximum annual savings up to $1,500. Please click here for full terms and conditions for the PAXCESSTM
Co-Pay Savings Program.
†The USG PAP operated by Pfizer is an independent program with separate eligibility requirements offered by the United States Department of Health and Human Services and is not
owned by Pfizer. Please click here for the full terms and conditions of the USG PAP.
Many adults are living with at least 1 risk factor that puts them at high risk for progression to severe COVID-19 and may benefit from early treatment with PAXLOVID.
Learn about the BOXED WARNING, contraindications, managing concomitant medications, and which medications to avoid with PAXLOVID.
Discover the safety data from the EPIC-HR trial.
Have a question about PAXLOVID?
Request a visit from a product representative.
Drugs that are strong CYP3A inducers: PAXLOVID cannot be started immediately after discontinuation of any of the following medications due to the delayed offset of the recently discontinued CYP3A inducer:
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
Limitations of Use
PAXLOVID is not approved for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19.